Oxford BioMedica encouraged by phase I/II Parkinson’s trial

pharmafile | July 15, 2009 | News story | Research and Development |  Oxford BioMedica, Prosavin 

Related Content

Oxford Biomedica acquires ABL Europe for €15m

Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut …

shutterstock_2

Oxford Biomedica joins forces with UK’s Vaccines Manufacturing and Innovation Centre to scale up production of Oxford Uni’s COVID-19 vaccine

Oxford Biomedica has forged a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) …

novo_flag

Novo Holdings invests £53.5 million into Oxford Biomedica

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for …

The Gateway to Local Adoption Series

Latest content